NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

• Market Cap: $3.62B
• Dividend Yield: N/A
• Average Volume (3M): 895.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.61
• Shares Outstanding: 113,390,800
• 10 Day Avg. Volume: 764,070
• 30 Day Avg. Volume: 895,767
• PEG Ratio: -0.53
• Price to Book (P/B): 3.20
• Price to Sales (P/S): 53.22
• P/FCF Ratio: -15.23
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 76.05
• Enterprise Value/Gross Profit: 76.05
• Enterprise Value/Ebitda: -9.30
• 1Y Price Target: $48.63
• Price Target Upside: 52.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -1.62
• Revenue Forecast (FY): $45.04M

• Rating: 55 Neutral
• Price Target: $37.00 ▲(16.24% Upside)

The score is primarily held back by weak financial performance (large losses and continued cash burn despite some improvement) and only neutral technical signals. Offsetting these risks are a strong, low-debt balance sheet and a constructive corporate update with meaningful clinical/regulatory milestones and a stated funding runway.

Positive Factors

Strong balance sheet

Very low leverage and a large equity base provide durable financial optionality. This supports continued funding of multiple Phase 3 programs, reduces near-term refinancing risk, and enhances the company's ability to negotiate partnerships or commercial investments ahead of pivotal readouts.

Regulatory progress (EMA)

Acceptance of MAAs and an anticipated 2H‑2026 decision materially de-risks the European commercialization pathway. A favorable regulatory outcome would shift the company from pure clinical development to market access planning, changing long-term cash generation prospects and partner dynamics.

Broad Phase 3 program & enrollment

Large PREVAIL enrollment and multiple Phase 3 programs diversify clinical risk and increase statistical power for outcomes. Expansion into neurodegeneration broadens addressable markets, making long‑term commercial potential less binary and more strategic for partners and payers.

Negative Factors

Persistent cash burn

Sustained negative operating and free cash flow indicate the company is consuming cash to fund development. Even with ample cash on hand today, ongoing burn requires continued financing, partnerships, or successful commercialization to avoid dilution or spending constraints over the medium term.

Sharp revenue decline

A nearly 45% revenue drop reduces internal funding capacity and highlights limited commercial traction pre-approval. For a clinical-stage biotech, declining revenues amplify dependence on external capital and magnify execution risk until regulatory approvals enable sustainable sales.

Deep losses and negative returns

Very large net losses and negative returns reflect high R&D and SG&A relative to revenue. These poor profitability metrics can lead to equity dilution when funding, constrain reinvestment capacity, and mean long-term value depends heavily on successful trial outcomes and commercialization.

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

How the Company Makes Money

NewAmsterdam Pharma generates revenue primarily through the commercialization of its pharmaceutical products, which are sold to healthcare providers, hospitals, and pharmacies. The company may also engage in strategic partnerships with larger pharmaceutical firms for joint development and marketing of its drug candidates, which can provide additional income through upfront payments and royalties on sales. Research grants and funding from government and private entities for clinical trials and product development may also contribute to its revenue. Additionally, licensing agreements for its intellectual property could serve as significant revenue streams, enhancing the company's financial stability.

NewAmsterdam Pharma Company Financial Statement Overview

Summary

NewAmsterdam Pharma Company exhibits typical characteristics of a biotech firm with high R&D expenses leading to operational losses. While revenue growth is promising, profitability remains a challenge. The balance sheet is strong with low leverage, providing stability. Cash flows are negative, but capital raising efforts support liquidity. The company must focus on achieving profitability to ensure long-term sustainability.

Income Statement

The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.

Cash Flow

Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.24M	45.56M	14.09M	102.69M	0.00	0.00
Gross Profit	35.24M	45.56M	14.09M	102.69M	0.00	0.00
EBITDA	-288.10M	-241.49M	-176.86M	-22.34M	-41.37M	-6.63M
Net Income	-221.07M	-241.60M	-176.94M	-22.63M	-41.78M	-7.02M
Balance Sheet
Total Assets	786.43M	864.62M	347.10M	478.50M	67.99M	139.87M
Cash, Cash Equivalents and Short-Term Investments	702.95M	834.19M	340.45M	467.73M	60.38M	1.37M
Total Debt	266.00K	448.00K	60.00K	126.00K	186.51K	0.00
Total Liabilities	58.36M	107.12M	58.70M	48.43M	11.36M	12.41M
Stockholders Equity	728.07M	757.50M	288.39M	430.07M	56.63M	127.46M
Cash Flow
Free Cash Flow	-144.54M	-159.24M	-141.24M	10.44M	-29.54M	―
Operating Cash Flow	-144.39M	-158.56M	-141.22M	10.66M	-29.51M	―
Investing Cash Flow	-215.95M	-62.85M	-24.00K	-221.00K	-24.00K	―
Financing Cash Flow	472.45M	659.51M	8.91M	391.90M	84.70M	13.92M

NewAmsterdam Pharma Company Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 31.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 31.83 is below the 20-day moving average (MA) of 34.38, below the 50-day MA of 36.32, and above the 200-day MA of 26.65, indicating a neutral trend. The MACD of -1.01 indicates Positive momentum. The RSI at 36.28 is Neutral, neither overbought nor oversold. The STOCH value of 10.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.

NewAmsterdam Pharma Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	70 Outperform	$3.00B	84.57	7.39%	―	55.68%	―
XENE	59 Neutral	$3.21B	-10.49	-45.14%	―	―	-38.30%
IMVT	56 Neutral	$5.51B	-9.19	-95.93%	―	―	-27.70%
NAMS	55 Neutral	$3.62B	-15.59	-39.94%	―	―	―
SLNO	53 Neutral	$2.28B	-22.77	-20.66%	―	―	44.84%
VKTX	52 Neutral	$3.88B	-15.05	-29.23%	―	―	-126.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

NewAmsterdam Pharma Company Corporate Events

NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress

On January 9, 2026, NewAmsterdam Pharma highlighted its 2025 clinical and regulatory progress for obicetrapib and set out key goals for 2026, underscoring its push toward commercialization in cardiovascular disease and potential expansion into neurodegeneration. In 2025, the company reported statistically significant reductions in Alzheimer’s disease biomarker p-tau217 from the Phase 3 BROADWAY trial, presented pooled Phase 3 efficacy and safety data for obicetrapib at major cardiology forums, and secured EMA validation of marketing applications for obicetrapib monotherapy and an obicetrapib/ezetimibe fixed-dose combination in hypercholesterolemia, with a European approval decision anticipated in the second half of 2026. Operationally, NewAmsterdam advanced three Phase 3 programs—PREVAIL, REMBRANDT and RUBENS—completed PREVAIL enrollment at over 9,500 patients, began RUBENS enrollment in December 2025, and plans to launch a dedicated early Alzheimer’s disease trial in 2026, leveraging emerging links between CETP inhibition and neurodegeneration. With approximately $729 million in unaudited cash, cash equivalents and marketable securities at year-end 2025, the company expects to be funded through the PREVAIL cardiovascular outcomes readout and a potential subsequent U.S. commercial launch, positioning it as a significant emerging player in the crowded LDL-C–lowering market and offering potential upside for partners and future shareholders if pivotal data and regulatory reviews are favorable.

The most recent analyst rating on (NAMS) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

NewAmsterdam Pharma Achieves Key EMA Regulatory Milestone

On November 5, 2025, NewAmsterdam Pharma announced its third-quarter financial results and provided a corporate update. The company reported a significant regulatory milestone with the European Medicines Agency’s acceptance of marketing authorization applications for obicetrapib and its fixed-dose combination with ezetimibe. Despite a decrease in revenue and an increase in net loss compared to the previous year, NewAmsterdam continues to advance its clinical development strategy and build global infrastructure to support the potential launch of obicetrapib. The company also highlighted its ongoing trials and upcoming milestones, emphasizing its commitment to providing a differentiated therapy in the cardiovascular market.

The most recent analyst rating on (NAMS) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.